CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
The goal of this clinical trial is to compare participants with ovarian, fallopian tube or primary peritoneal cancer when treated w...
Phase 2
Durham, North Carolina, United States and 25 other locations
followed by maintenance durvalumab and bevacizumab or durvalumab, bevacizumab and olaparib in patients with newly diagnosed advanced ovarian ...
Phase 3
Durham, North Carolina, United States and 213 other locations
Olaparib Monotherapy in Patients with BRCA Mutated Ovarian Cancer following First Line Platinum Based Chemotherapy....
Phase 3
Durham, North Carolina, United States and 176 other locations
positive, recurrent platinum sensitive, high-grade epithelial ovarian, primary peritoneal, or fallopian tube cancer following 1 pri...
Phase 2
Durham, North Carolina, United States and 70 other locations
the safety and activity of oregovomab and niraparib as a combinatorial immune priming strategy in subjects with platinum sensitive recurrent ovarian...
Phase 2
Durham, North Carolina, United States and 2 other locations
within each cohort-specific supplement in participants with ovarian, fallopian tube, or primary peritoneal cancer. Cohort A (single ...
Phase 2
Durham, North Carolina, United States and 32 other locations
This is a Phase 1b open-label, multicenter study, evaluating the safety, tolerability, preliminary clinical activity, pharmacokinetics (PK), and phar...
Phase 1
Durham, North Carolina, United States and 23 other locations
peripheral neuropathy (CIPN) in patients with recurrent ovarian and endometrial cancers, which are among the most lethal gynecologi...
Phase 1, Phase 2
Durham, North Carolina, United States
Patients will be registered prior to, during or at the completion of neoadjuvant chemotherapy (Paclitaxel 175 mg/m2 IV over 3 hours and Carboplatin A...
Phase 3
Durham, North Carolina, United States and 50 other locations
This study aims to assess efficacy of Niraparib (GSK3985771) as maintenance treatment in participants with Stage III or IV ovarian cancer...
Phase 3
Chapel Hill, North Carolina, United States and 196 other locations
Clinical trials
Research sites
Resources
Legal